Published on 11 Nov 2024 on Benzinga
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says...
On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.